Philip A Leighton
Overview
Explore the profile of Philip A Leighton including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vuong C, Reynolds K, Rivera G, Zeng B, Karimpourkalou Z, Norng M, et al.
MAbs
. 2024 Nov;
16(1):2435476.
PMID: 39607037
Heavy chain-only antibodies have found many applications where conventional heavy-light heterodimeric antibodies are not favorable. Heavy chain-only antibodies with their single antigen-binding domain offer the advantage of a smaller size...
2.
Leighton P, Ching K, Reynolds K, Vuong C, Zeng B, Zhang Y, et al.
J Immunol
. 2024 Apr;
212(11):1744-1753.
PMID: 38629917
H chain-only Igs are naturally produced in camelids and sharks. Because these Abs lack the L chain, the Ag-binding domain is half the size of a traditional Ab, allowing this...
3.
Ching K, Berg K, Reynolds K, Pedersen D, Macias A, Abdiche Y, et al.
MAbs
. 2021 Jan;
13(1):1862451.
PMID: 33491549
Bispecific antibodies are an important and growing segment in antibody therapeutics, particularly in the immuno-oncology space. Manufacturing of a bispecific antibody with two different heavy chains is greatly simplified if...
4.
Cameron B, Dabdoubi T, Berthou-Soulie L, Gagnaire M, Arnould I, Severac A, et al.
PLoS One
. 2020 Jul;
15(7):e0235815.
PMID: 32673351
Monoclonal antibodies (mAbs) for therapeutic applications should be as similar to native human antibodies as possible to minimize their immunogenicity in patients. Several transgenic animal platforms are available for the...
5.
Ching K, Berg K, Morales J, Pedersen D, Harriman W, Abdiche Y, et al.
PLoS One
. 2020 Jan;
15(1):e0228164.
PMID: 31995598
Most of the approved monoclonal antibodies used in the clinic were initially discovered in mice. However, many targets of therapeutic interest are highly conserved proteins that do not elicit a...
6.
Collarini E, Leighton P, van de Lavoir M
Methods Mol Biol
. 2018 Oct;
1874:403-430.
PMID: 30353528
The unique characteristics of the avian embryo, with its large opaque yolk, have necessitated the development of different approaches to transgenesis from those that have been successful in mammalian species....
7.
Leighton P, Morales J, Harriman W, Ching K
Front Immunol
. 2018 Jun;
9:1317.
PMID: 29951062
An important characteristic of chickens is that the antibody repertoire is based on a single framework, with diversity found mainly in the CDRs of the light and heavy chain variable...
8.
Ching K, Collarini E, Abdiche Y, Bedinger D, Pedersen D, Izquierdo S, et al.
MAbs
. 2017 Oct;
10(1):71-80.
PMID: 29035625
Transgenic animal platforms for the discovery of human monoclonal antibodies have been developed in mice, rats, rabbits and cows. The immune response to human proteins is limited in these animals...
9.
Schusser B, Collarini E, Pedersen D, Yi H, Ching K, Izquierdo S, et al.
Eur J Immunol
. 2016 Jul;
46(9):2137-48.
PMID: 27392810
Since the discovery of antibody-producing B cells in chickens six decades ago, chickens have been a model for B-cell development in gut-associated lymphoid tissue species. Here we describe targeting of...
10.
Dimitrov L, Pedersen D, Ching K, Yi H, Collarini E, Izquierdo S, et al.
PLoS One
. 2016 Apr;
11(4):e0154303.
PMID: 27099923
The CRISPR/Cas9 system has been applied in a large number of animal and plant species for genome editing. In chickens, CRISPR has been used to knockout genes in somatic tissues,...